Pharmaceuticals company Piramal Pharma announced Q4FY26 & FY26 results Q4FY26 Standalone Financial Highlights: Revenue from Operations: Rs 1,489.06 crore in Q4FY26, up 24.52% QoQ from Rs 1,195.81 crore and down 11.88% YoY from Rs 1,689.80 crore. Other Income (Net): Rs 183.69 crore for the quarter, up 91.05% QoQ from Rs 96.15 crore and up 364.92% YoY from Rs 39.51 crore. Total Income: Rs 1,672.75 crore in Q4FY26, compared to Rs 1,291.96 crore in Q3FY26 (up 29.47% QoQ) and Rs 1,729.31 crore in Q4FY25 (down 3.27% YoY). Profit After Tax: Rs 261.63 crore for the quarter, up 102.96% QoQ from Rs 128.91 crore and down 5.64% YoY from Rs 277.27 crore. Total Comprehensive Income: Rs 251.49 crore in Q4FY26, showing a QoQ growth of 88.45% from Rs 133.45 crore and a YoY decrease of 13.49% from Rs 290.70 crore. Earnings Per Share (EPS): Basic EPS stood at Rs 1.97 for the quarter, compared to Rs 0.97 in Q3FY26 and Rs 2.09 in Q4FY25. Q4FY26 Consolidated Financial Highlights: Revenue from Operations: Rs 2,751.77 crore in Q4FY26, up 28.59% QoQ from Rs 2,139.87 crore and down 0.08% YoY from Rs 2,754.07 crore. Total Income: Rs 2,797.83 crore for the quarter, up 28.16% QoQ from Rs 2,183.11 crore and up 0.06% YoY from Rs 2,796.10 crore. Net Profit / (Loss) After Tax: Reported a reduced loss of Rs 8.82 crore in Q4FY26, compared to a loss of Rs 136.20 crore in Q3FY26. This compares to a profit of Rs 153.50 crore in Q4FY25. Total Comprehensive Income: Rs 154.47 crore for the quarter, compared to a loss of Rs 76.16 crore in Q3FY26 and a profit of Rs 167.45 crore in Q4FY25 (down 7.75% YoY). Earnings Per Share (EPS): Basic EPS was Rs (0.07) for the quarter, against Rs (1.03) in Q3FY26 and Rs 1.16 in Q4FY25. FY26 Standalone Financial Highlights: Revenue from Operations: Rs 4,782.01 crore in FY26, down 9.53% YoY from Rs 5,285.71 crore in FY25. Total Income: Rs 5,444.74 crore for FY26, compared to Rs 5,493.06 crore in FY25. Profit After Tax: Rs 700.01 crore for the full year, up 1.25% YoY from Rs 691.40 crore. Net Cash generated from Operating Activities: Rs 1,328.12 crore in FY26, a significant increase of 142.02% YoY from Rs 548.77 crore in FY25. Earnings Per Share (EPS): Basic EPS for FY26 was Rs 5.28, up from Rs 5.22 in FY25. FY26 Consolidated Financial Highlights: Revenue from Operations: Rs 8,869.08 crore in FY26, down 3.08% YoY from Rs 9,151.18 crore in FY25. Total Income: Rs 9,082.38 crore for the full year, down 2.19% YoY from Rs 9,285.99 crore. Net Profit / (Loss) After Tax: Reported a net loss of Rs 325.94 crore for FY26, compared to a profit of Rs 91.13 crore in FY25. Net Cash generated from Operating Activities: Rs 1,652.59 crore in FY26, up 85.21% YoY from Rs 892.30 crore in FY25. Earnings Per Share (EPS): Basic EPS for the year was Rs (2.46), compared to Rs 0.69 in FY25. Business Highlights: Leadership Re-appointments: The Board approved the re-appointment of Ms. Nandini Piramal as Executive Director and Chairperson for 3 years starting April 1, 2027. Mr. Peter DeYoung was also re-appointed as Executive Director for 3 years effective October 6, 2026. Independent Directors: Mr. Sridhar Gorthi and Mr. Peter Stevenson were re-appointed as Non-Executive, Independent Directors for a second 5-year term starting March 30, 2027. Key Managerial Personnel Changes: Mr. Maneesh Sharma was appointed as Company Secretary and Compliance Officer (KMP) effective April 29, 2026, succeeding Ms. Pratibha Mishra. Registered Office Change: The Company’s registered office address was changed to Ananta Building, Piramal Corporate Park, Kurla (West), Mumbai, effective April 30, 2026. Strategic Acquisition: Step-down subsidiary Piramal Critical Care B.V. completed the acquisition of Kenalog and associated brands from Bristol Myers Squibb Company on April 1, 2026, for an upfront consideration of USD 35 million and contingent payments of up to USD 65 million. Impairment Charges: The Company recognized materiality-driven impairment charges on certain intangible assets under development amounting to Rs 65.57 crore in Standalone results and Rs 175.82 crore in Consolidated results for FY26. Forex Gains: Total income for the year includes a significant Foreign Exchange Gain of Rs 381.82 crore. Labour Code Impact: The Company assessed and presented an incremental impact of Rs 26.94 crore in FY26 related to changes in the new Labour Codes (gratuity and other provisions). Nandini Piramal, Chairperson, Piramal Pharma, said: “FY26 was a transitional year, shaped by external disruptions and certain business-specific factors. Despite these challenges, we exited the year on a stronger note, with clear momentum across all our businesses. The meaningful recovery in biopharma funding seen from Sep’25, is translating into good RFP momentum and healthy pick up in order inflows in our CDMO business. In the CHG business, the recently completed Kenalog® acquisition alongside ramp up of inhalation anesthesia sales in ex-US markets are expected to be key growth drivers. Our Consumer Healthcare business is also well positioned to sustain its growth momentum with margin improvement driven by Power Brands and rapid growth in e?commerce. Overall, all three businesses are well positioned to deliver growth in FY27, accompanied by accelerated growth in EBITDA and PAT.” Result PDF